Journal of Zhejiang University SCIENCE
(ISSN 1009-3095, Monthly)

2005   Vol. 6B   No. 5   p.446-450

Pharmacokinetics of gemcitabine in Chinese patients with non-small-cell lung cancer

WANG Lin-run^†, HUANG Ming-zhu, XU Nong, SHENTU Jian-zhong, LIU Jian, CAI Jie

(First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China)
^†E-mail: linrunw@yahoo.com.cn
Received Feb. 2, 2005; revision accepted Mar. 3, 2005

Abstract: To determine the pharmacokinetics of gemcitabine (2′,2′-difluorodeoxycytidine) in Chinese non-small-cell lung cancer (NSCLC) patients. Six study subjects were administered gemcitabine at a fixed dose rate of 10 mg/m² per min (1200 mg/m², two hours infusion), and carboplatin and plasma gemcitabine concentrations were measured by ion-pair reversed-phase high-performance liquid chromatography (HPLC). 3P97 Pharmaceutical Kinetics Software was used for the calculation of pharmacokinetic parameters. The obtained mean parameters, elimnation half life (t_1/2) (10.67±3.38 min), area under the curve (AUC) (7.55±1.53 (µg·h)/ml), and clearance (CL) (3940.05±672.08 ml/min), were consistent with those reported in literature. The hematologic toxicology result showed that the regimen was effective on and tolerated by the patients.

Key words: Gemcitabine, Non-small-cell lung cancer, Pharmacokinetics
doi:10.1631/jzus.2005.B0446             CLC number: R9